1. U.S. Food and Drug Administration. FDA News Release: FDA approves first new drug under international collaboration, a treatment option for patients with HER2-positive metastatic breast cancer. fda.gov https://www.fda.gov/news-events/press-announcements/fda-approves-first-new-drug-under-international-collaboration-treatment-option-patients-her2 (2020).
2. de Claro, R. A. et al. Project Orbis: Global Collaborative Review Program. Clin. Cancer Res. 26, 6412–6416 (2020).
3. U.S. Food and Drug Administration. Oncology center of excellence guidance documents. fda.gov https://www.fda.gov/about-fda/oncology-center-excellence/oncology-center-excellence-guidance-documents (2020).
4. U.S. Food and Drug Administration. Project patient voice. fda.gov https://www.fda.gov/about-fda/oncology-center-excellence/project-patient-voice (2020).
5. Cavallo J. Efforts to broaden eligibility criteria for clinical trials seek to include more racial and ethnic minority patients: a conversation with Lola A. Fashoyin-Aje, MD, MPH. The ASCO Post https://ascopost.com/issues/september-25-2020/efforts-to-broaden-eligibility-criteria-for-clinical-trials-seek-to-include-more-racial-and-ethnic-minority-patients/ (2020).